Functionally significant polymorphisms of ESR1 and PGR and risk of intrauterine growth restriction in population of Central Russia
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
Authors: Golovchenko, Oleg; Abramova, Maria; Ponomarenko, Irina; Reshetnikov, Evgeny; Aristova, Inna; Polonikov, Alexey; Dvornyk, Volodymyr; Churnosov, Mikhail
Abstract
Objective: This study aimed to investigate the role of ESR1 and PGR gene polymorphisms in development of intrauterine growth restriction (IUGR) among Russian women in Central Russia. Study design: This case-control study recruited a total of 520 women in the third trimester of pregnancy, including 196 IUGR patients and 324 controls. The participants were unrelated women of self-reported Russian ethnicity. Participants were genotyped at 4 functionally significant polymorphisms of the ESR1 (rs2234693, rs9340799) and the PGR (rs484389, rs1042838) genes. The association analysis was performed using logistic regression. Two polymorphisms, which were associated with IUGR, and 26 polymorphisms linked to them (r(2) >= 0.6) were analyzed for their functional significance in silico. Results: Haplotype TG of loci rs2234693-rs9340799ESR1 (OR = 1.94, P-perm = 0.006) was associated with an increased risk of IUGR. Allele T of rs2234693 decreases expression of ESR1 in thyroid gland, allele T of rs2234693 and allele G of rs9340799 increase affinity to eight transcription factors (AP-4, HEN1, E2A, LBP-1, RP58, LUN, Ets and Hand). The loci that are linked (r(2) >= 0.6) to the IUGR-associated SNPs, have the cis-eQTL value (expression ESR1 in thyroid gland) and showed their regulatory effects in organs and tissues related to pathogenesis of IUGR. Conclusion: Haplotype TG defined by polymorphisms rs2234693-rs9340799 of the ESR1 gene is associated with the development of IUGR in Russian women from Central Russia. (C) 2020 Elsevier B.V. All rights reserved.
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
FRONTIERS IN ONCOLOGY
Authors: Schroers, Barbara; Boegel, Sebastian; Albrecht, Christian; Bukur, Thomas; Bukur, Valesca; Holtstraeter, Christoph; Ritzel, Christoph; Manninen, Katja; Tadmor, Arbel D.; Vormehr, Mathias; Sahin, Ugur; Loewer, Martin
Abstract
Background:Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely used breast cancer models. Here, we present an integrated map of the genome, transcriptome, and immunome of 4T1. Results:We found Trp53 (Tp53) and Pik3g to be mutated. Other frequently mutated genes in breast cancer, including Brca1 and Brca2, are not mutated. For cancer related genes, Nav3, Cenpf, Muc5Ac, Mpp7, Gas1, MageD2, Dusp1, Ros, Polr2a, Rragd, Ros1, and Hoxa9 are mutated. Markers for cell proliferation like Top2a, Birc5, and Mki67 are highly expressed, so are markers for metastasis like Msln, Ect2, and Plk1, which are known to be overexpressed in triple-negative breast cancer (TNBC). TNBC markers are, compared to a mammary gland control sample, lower (Esr1), comparably low (Erbb2), or not expressed at all (Pgr). We also found testis cancer antigen Pbk as well as colon/gastrointestinal cancer antigens Gpa33 and Epcam to be highly expressed. Major histocompatibility complex (MHC) class I is expressed, while MHC class II is not. We identified 505 single nucleotide variations (SNVs) and 20 insertions and deletions (indels). Neoantigens derived from 22 SNVs and one deletion elicited CD8(+)or CD4(+)T cell responses in IFN gamma-ELISpot assays. Twelve high-confidence fusion genes were observed. We did not observe significant downregulation of mismatch repair (MMR) genes or SNVs/indels impairing their function, providing evidence for 6-thioguanine resistance. Effects of the integration of the murine mammary tumor virus were observed at the genome and transcriptome level. Conclusions:4T1 cells share substantial molecular features with human TNBC. As 4T1 is a common model for metastatic tumors, our data supports the rational design of mode-of-action studies for pre-clinical evaluation of targeted immunotherapies.